Clinical Trials Search among the pediatric clinical trials we have open at the Vall d'Hebron Research Institute. Malaltia - Any -Acute lymphoblastic leukemiaAcute Myeloid Leukemia (Pediatric 0-18 years)Adolescent Renal AllograftsAdrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency).Advanced solid tumorsAllergic rhinoconjunctivitis due to exposure of house dust mitesAsthmaAtaxia TelangiectasiaAtaxia Telangiectasia (A-T)Atopic DermatitisAtrofia muscular espinalAutosomal Recessive Polycystic Kidney DiseaseB-Cell Acute Lymphoblastic LeukaemiaB-cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL).Biliary AtresiaBiliary Atresia, Post-hepatoportoenterostomyCélulas Falciformes con crisis vaso-oclusivas.Certain infectious and parasitic diseasesCertes afeccions originades en el període perinatalChronic kidney disease / ProteinuriaCirculatory system diseasesClassic Congenital Adrenal Hyperplasia (CAH)Codis per situacions especialsComplement 3 glomerulopathyCongenital atransferrinaemia/ hypotransferrinaemiaDeficiencia de timidina quinasa 2Digestive system diseasesDiseases of the blood and hematopoietic organs and certain disorders that affect the mechanism of immunityDiseases of the ear and mastoid processDiseases of the eye and its adnexaDiseases of the genitourinary systemDiseases of the musculoskeletal system and connective tissueDiseases of the respiratory systemDiseases of the skin and subcutaneous tissueDistrofia muscular de DuchenneDravet and Lennox-Gastaut SyndromesDravet syndrome or Lennox-Gastaut syndromeDuchenne muscular dystrophyPregnancy, childbirth and puerperiumEndocrine, nutritional and metabolic diseasesEnfermedad Pulmonar Intersticial Nervous system diseasesEpilepsia relacionada con CET Episodic MigraineFactors influencing health status and contact with health servicesGlomerulopatía C3 primaria o glomerulonefritis membranoproliferativa mediada por inmunocomplejos Haemophilia AHaemophilia A or B with or without inhibitorsHeart failure due to systemic left ventricular systolic dysfunctionHematologic Malignancies or Solid Tumors in Pediatric and Young AdultsHemofilia A con inhibidores Hepatoblastoma y carcinoma hepatocelularHereditary Angioedema Type I or IIHerpes zóster en sujetos inmunodeprimidosHiperoxaluria Primaria Hipotensión resistente a las catecolaminas asociada a shock distributivoHypoglycemia associated with congenital hyperinsulinismImmune Thrombocytopenia (ITP)Injuries, poisoning and some other consequences of external causesIrritability associated with autistic disorder in children and adolescents with ASDJuvenile psoriatic arthritisLeucodistrofia metacromática tardíaLinfoma de HodgkinMalformacions congènites, deformitats i anomalies cromosòmiquesMedulloblastomaMental and behavioral disordersMigrañaModerately to severely active ulcerative colitisMucopolysaccharidosis Type IIMucopolysaccharidosis type IIIANefritis lúpica NeuroblastomaOral ulcers associated with Behçets Disease / Behcet's diseaseOsteosarcoma recidivado o resistente al tratamiento Paroxysmal Nocturnal Hemoglobinuria (PNH)Partial-onset (focal) seizuresPatients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1)Patologías del sistema immunitario. Seguimiento a largo plazo de pacientes expuestos a la terapia lentiviral con células CAR-TPrevención de la neumonía nosocomial Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseasePrimary HyperoxaluriaProteinuric glomerular diseases including: Focal segmental glomerulosclerosis (FSGS) Minimal change disease (MCD) Immunoglobulin A nephropathy (IgAN) Immunoglobulin A vasculitis (IgAV) Alport syndrome (AS)Pulmonary arterial hypertensionPyruvate Kinase DeficiencyRelapsed or refractory extracranial solid tumors in children and adolescentsRelapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)Relapsed/Refractory Aggressive Mature B-cell NeoplasmsRelapsed/refractory neuroblastoma and other solid tumoursRhabdoyosarcomaSevere asthma with an eosinophilic phenotypeSevere Uncontrolled AsthmaSickle cell diseaseSymptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classifiedSmall for gestational age / Idiopathic short stature / Noonan syndrome / Turners syndromeSolid TumoursSpinal Muscular Atrophy (SMA)Stereotypical prolonged seizureTRASTORNO DEL ESPECTRO AUTISTA (TEA) Tratamiento de la irritabilidad asociada al trastorno autista en niños y adolescentes con TEA. Treatment of children with chronic kidney disease and proteinuriaTreatment of stereotypical prolonged seizureTuberous Sclerosis Complex (TSC) related epilepsyTumorsTumores sólidos o primarios del sistema nervioso central con alteración avanzada de RETUlcerative Colitis Fàrmac - Any - Glycopyrronium (bromide)ABO-102 (scAAV9.U1a.hSGSH)AloCelyvir with chemotherapy and radiotherapyAnticuerpo monoclonal recombinante antiGDch14.18.ApotransferrinApremilastAtogepantAucatzylAurora Kinase A Inhibitor LY3295668 erbumineAUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPYAutologous, differentiated, peripheral blood T-cells expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) coupled with 4-1BB and CD3z co-stimulatory regions (ARI-0001 cells)AZD0486Belatacept-based Immunosuppressive RegimenC5VD, SIOPEL-3 high risk, cisplatin monotherapy, GEMOXCenobamate (YKP3089)Combination pyrimidine nucleos(t)idesConcizumabCrinecerfont (NBI-74788)CrizanlizumabCrizanlizumab, with or without Hydroxyurea/HydroxycarbamideCROVALIMABDCR PHXC Solution for Injection (subcutaneous use)DCR-PHXCDECOPDAC-21 protocol +/- radiationDYNE-251ENTR-601-45EpcoritamabErenumabEryDexEtrasimodFinerenone Frexalimab, SAR442970, or RilzabrutinibGalcanezumabGanaxolone (GNX)GemcitabineGIVINOSTATGNXGSK3511294 (Depemokimab)HydrocortisoneIntrathecal SHP611Iptacopan (LNP023)Irinotecan with IVA (IrIVA).KVD900 (oral Plasma Kallikrein Inhibitor)LasmiditanLebrikizumabLentiviral-Based CD19 directed CAR T-Cell TherapyLJPC-501MitapivatNedosiran neuraxis irradiation + chemotherapyNintedanibNIRAPARIB AND DOSTARLIMABNNC0365-3769 (Mim8)NOPHO-DBH AML 2012 ProtocolNusinersen (BIIB058)Obeticholic AcidOdevixibat (A4250) Odevixibat Oral RET Inhibitor LOXO-292PegcetacoplanPF-06939926PimavanserinRecombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) Repotrectinib Ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) Rilzabrutinib (PRN1008)RO7017773RO7204239 IN COMBINATION WITH RISDIPLAM (RO7034067)RZ358ScAAV9.U1a.hSGSHSomapacitanSotatercept (MK-7962)SoticlestatSparsentanStaccato AlprazolamSubcutaneous immunotherapy (Beltavac®) subunit candidate vaccine (PED-HZ/su) SuvratoxumabTezepelumabTividenofusp Alfa (DNL310)TolvaptanTPX-0005UpadacitinibVericiguatVoclosporinZilovertamab vedotinaZX008 (Fenfluramine Hydrochloride) bevacizumab added to temozolomide ± irinotecan Fase - Any -Phase IPhase IIPhase IIIPhase IV Reclutant - Any -YesNo Alphabetic A-Z Alphabetic Z-A Malaltia Fàrmac Phase Recruitment Informació Tuberous Sclerosis Complex (TSC) related epilepsy GNX Phase III No Més informació Tumores sólidos o primarios del sistema nervioso central con alteración avanzada de RET Oral RET Inhibitor LOXO-292 Phase I No Més informació Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5
